Accelerate to discover
Related topics
xCELLigence system: rapid and sensitive, ideal for infectious viral assays.
Mar 30, 2020
As the public health threat from COVID-19 and future emergent viruses continue to persist, the rapid, sensitive, and...
IncuCyte webinar: Organoids, iPSCs, and advanced cell models.
Mar 24, 2020
Researchers are now moving from reductionist, 2D monoculture assay models to more complex 3D cell models, such as...
IncuCyte live cell analysis system for 3D Organoids discovery
Mar 18, 2020
Live-Cell Analysis has revolutionized numerous studies, with a wide selection of applications namely 3D Tumour Spheroid...
Webinar recording: Ex vivo microangioCT, advances in microvascular imaging
Mar 16, 2020
A new technique called microangioCT imaging is being used with a novel polymerizing contrast agent that enables 3D...
Single Cell Sequencing sample preparation without centrifugation
Mar 10, 2020
Single-cell genomics is rapidly growing. Nature Methods named multimodal omics the method of the year for 2019. And as...
Introducing Amnis CellStream - Ultra-high sensitivity and flexibility
Mar 6, 2020
The new CellStream Benchtop flow cytometer delivers unparalleled sensitivity and flexibility for cell and particle...
Hitachi Koki - World leader for Ultracentrifuges & High-Speed Centrifuges
Mar 3, 2020
Hitachi Koki, as a world leading producer of centrifuges offers general purpose floor standing and table top...
Bioflux webinar: genetic control of antifungal resistance in Candida albicans
Feb 25, 2020
Candida albicans is the most common fungal species of humans, residing on the skin, in the gut, and in the oral cavity...
Nov 22, 2018
Researchers developed an assay to measure CLL cell interactions with endothelium under shear force using a Bioflux 200 and blocked CD62L using the anti-CD62L antibody DREG-56. CLL cell interactions with endothelium were visualized by time-lapse microscopy and CLL cell movement was tracked and quantified. Data will be discussed in the webinar and will establish targeting CD62L inhibits CLL cell/endothelial cell interactions and is accentuated by co-administration with ibrutinib. These data imply that some of the clinical effects caused by ibrutinib are due to a reduced capacity of CLL cells to engage endothelium and extravasate.
Dr. Chris Pepper, Professor in Cancer Studies, University of Sussex, UK
Related technologies: Cell interaction studies
Get more info
Brand profile
With BioFlux System for live cell analysis under shear flow and IsoFlux System for circulating tumor cell analysis, Fluxion Biosciences turn power of benchtop cellular analysis with advanced tools to automate complex assays.
More info at:
www.fluxionbio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
